Suven Life Sciences has received four product patents, two each from New Zealand and Eurasia for its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2022 and 2025 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.

With these new patents, Suven has a total of nine granted New Zealand patents and eight granted Eurasian patents on NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase I or phase-II.

Venkat Jasti, CEO, said,“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has a an estimated $30 billion market potential globally and these patents are very important step in the execution of our strategy.”

Suven Life has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and schizophrenia.